INCR
InterCure Ltd.NASDAQHealthcare$0.76-1.32%ClosedMarket Cap: $41.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.31
P/S
0.69
EV/EBITDA
-7.94
DCF Value
$-29.71
FCF Yield
6.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
21.7%
Operating Margin
-17.8%
Net Margin
-19.5%
ROE
-8.7%
ROA
-4.8%
ROIC
-4.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2025 | $65.0M | 30.9% | $2.9M | $-852.0K | $-0.02 | — |
| Q1 2025 | $65.0M | 30.9% | $2.9M | $-852.0K | $-0.02 | — |
| Q4 2024 | $56.6M | 0.3% | $-38.9M | $-34.6M | $-0.79 | — |
| FY 2024 | $238.8M | 12.7% | $-67.2M | $-67.8M | $-1.42 | — |
| Q3 2024 | $56.6M | 0.3% | $-38.9M | $-34.6M | $-0.79 | — |
| Q2 2024 | $62.9M | 33.1% | $5.3M | $716.5K | $0.02 | — |
| Q1 2024 | $62.9M | 33.1% | $5.3M | $716.5K | $0.02 | — |
| Q4 2023 | $73.5M | 24.7% | $-26.7M | $-33.5M | $-0.75 | — |
| FY 2023 | $355.6M | 29.6% | $-41.6M | $-62.0M | $-1.36 | — |
| Q3 2023 | $73.5M | 24.7% | $-26.7M | $-33.5M | $-0.75 | — |
| Q2 2023 | $102.4M | 31.9% | $5.8M | $4.9M | $0.11 | — |
| Q1 2023 | $106.2M | 32.3% | $5.9M | $214.0K | $0.00 | — |